Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM3 | P20309 | 7/20 | 0.37 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.37 |
| ▸ | PAOX | Q6QHF9 | 1/20 | 0.35 |
| ▸ | BCHE | P06276 | 5/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | HTR7 | P34969 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26501244 | 0.92 | BCHE (0.41) | BCHESMN1; SMN2HTR7 | |
| SCHEMBL26501216 | 0.92 | PAOX (0.40) | CHRM3CHRM2PAOXHTR7 | |
| SCHEMBL26501222 | 0.92 | PAOX (0.40) | CHRM3CHRM2PAOXHTR7 | |
| SCHEMBL26501219 | 0.92 | PAOX (0.40) | CHRM3CHRM2PAOXHTR7 | |
| SCHEMBL26501223 | 0.92 | PAOX (0.40) | CHRM3CHRM2PAOXHTR7 | |
| SCHEMBL26501248 | 0.92 | PAOX (0.40) | CHRM3CHRM2PAOXHTR7 | |
| SCHEMBL26501233 | 0.92 | PAOX (0.40) | CHRM3CHRM2PAOXHTR7 | |
| SCHEMBL26501220 | 0.92 | PAOX (0.40) | CHRM3CHRM2PAOXHTR7 | |
| SCHEMBL26505018 | 0.88 | CHRM3 (0.37) | CHRM3CHRM2PAOXBCHESMN1; SMN2 | |
| SCHEMBL26501276 | 0.84 | CHRM3 (0.35) | CHRM3CHRM2PAOXBCHESMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230321253-A1 | BIFUNCTIONAL COMPOUNDS AND PHARMACEUTICAL USES THEREOF | Risen (Suzhou) Pharma Tech Co., Ltd. (CN) | 2023-10-12 | — | — | US | disclosed |
| US-20230321253-A1 | BIFUNCTIONAL COMPOUNDS AND PHARMACEUTICAL USES THEREOF | Risen (Suzhou) Pharma Tech Co., Ltd. (CN) | 2023-10-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230321253-A1 | BIFUNCTIONAL COMPOUNDS AND PHARMACEUTICAL USES THEREOF | KRAS, MDM2, NRAS | CHRM3 4809/4885CHRM2 4790/4885PAOX 1898/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.